Skip to content

Mar 2017, Volume 24, Issue 2

March’s edition of the EJHP includes an editorial on “Value or cost”, and original articles on: evaluation of a pharmaceutical assessment screening tool; biosimilar infliximab for the management of rheumatoid arthritis; the cost and efficiency of incident reporting in a specialist paediatric NHS hospital and impact on patient safety; ready-to-use parenteral amiodarone; and much more.

The edition also contains a case report on bradycardia associated with pegylated liposomal doxorubicin administration, as well as a postcript on deprescribing in India: will we ever get down to it?. 

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.